Stéphane Bancel, CEO of pharmaceutical company and Covid-19 vaccine maker, Moderna Inc, has said that the company has the capacity to produce up to 500 million coronavirus vaccines by 2021.
The CEO disclosed this at the Nasdaq Investor Conference, as reported by Reuters.
READ: Nigeria, others to receive first-ever HIV generic drug for babies in the first half of 2021
What you should know
- Nairametrics reported last month that the pharmaceutical company had stated that its Covid-19 vaccine was 94.5% effective in treating coronavirus, after preliminary analysis of a large late-stage clinical trial.
- UK Health Secretary, Matt Hancock announced in November that the UK had secured 5 million doses of the vaccine.
The company disclosed that they had applied for emergency use of the vaccine in the United States and EU after finalizing clinical trials which showed 94.1% efficacy, and would hold a December 17 meeting with the American Food and Drug Administration to discuss emergency use.
READ: Covid-19: First world nations oppose waiving intellectual rights for vaccine development
“For 500 million, I am very comfortable we are gonna get there (2021),” Bancel said at the Nasdaq Investor Conference.
The CEO added that the price for its vaccine would remain at $37 per dose, but expected it to fall to $25 as purchase volumes rose.
Moderna says up to 125 million doses of its Covid-19 vaccine will be supplied globally by the first quarter of 2021.